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ncreased lipid availability is strongly associated with
both -cell dysfunction and insulin resistance, two
key facets of type 2 diabetes. Isoforms of the protein
kinase C (PKC) family have been viewed as candi-
dates for mediating the effects of fat oversupply because
they are lipid-dependent kinases with wide-ranging roles
in signal transduction, including the positive and negative
modulation of insulin action. Until recently, their involve-
ment was based on correlative studies, but now causative
roles for distinct PKC isoforms have also been addressed,
in both pancreatic -cells and insulin-sensitive tissues. Our
goal here, therefore, is to review the hitherto disparate
ﬁelds of PKC function in insulin signaling/resistance on the
one hand and in regulating -cell biology on the other
hand. By integrating these two areas, we provide a reap-
praisal of the current paradigm regarding PKC and type 2
diabetes. In particular, we propose that PKCε warrants
further investigation, not merely as a treatment for insulin
resistance as previously supposed, but also as a positive
regulator of insulin availability.
DIACYLGLYCEROL-MEDIATED ACTIVATION OF PROTEIN
KINASE C
The protein kinase C (PKC) family comprises 10 isoforms
that have been subdivided into three groups (Fig. 1) based
on sequence homology and mechanisms of activation (rev.
in 1). While differentiated by their sensitivity to Ca
2, both
the conventional PKCs (cPKC,- , and -) and novel PKCs
(nPKC,- ε ,- , and -) are dependent on diacylglycerol
(DAG) for full activation. These isoforms are therefore
responsive to the stimulation of G protein–coupled recep-
tors or receptor tyrosine kinases, which activate phospho-
lipase C, inducing the hydrolysis of phosphatidylinositol
4,5-bisphosphate at the plasma membrane and the result-
ant generation of DAG and Ca
2. Evidence for the acute
elevation of DAG in this fashion by insulin was reported in
early studies (2), although the identities of the putative
phospholipase(s) and phospholipid substrates involved
were never clariﬁed. On the other hand, chronic elevation
of DAG through de novo synthesis during periods of lipid
oversupply, as in the case of obesity, has been widely
correlated with cPKC and nPKC activation, although in
this case, DAG is ﬁrst synthesized in the endoplasmic
reticulum, perhaps resulting in PKC activation at intracel-
lular sites.
As a consequence of the interaction between PKC and
membrane-delimited DAG, cPKC and nPKC isoforms gen-
erally translocate from a cytosolic to a membrane-associ-
ated compartment. PKC isoform translocation, observed
by immunoblotting subcellular fractions, is thus com-
monly used as an indication of activation, particularly
because in vitro kinase assays discriminate poorly be-
tween isoforms. Longer-term stimulation leads to PKC
downregulation by proteolysis, although susceptibility var-
ies between isoforms and depends on cell type.
PKCs AS INSULIN SIGNAL TRANSDUCERS
The atypical isoforms (aPKC and aPKC	/
) constitute a
third group within the PKC family and are independent of
both Ca
2 and DAG (Fig. 1). (There is confusion in the
literature concerning PKC
 [3], which is not a distinct
isoform but in fact the mouse ortholog of human PKC	 [4].
In all species, the gene symbol for this isoform is now
Prkci.) Instead, these kinases can be activated in response
to stimulation of the insulin receptor substrate (IRS)/
phosphatidylinositol (PI) 3-kinase pathway, which enables
phosphorylation of aPKCs at the “activation loop” near the
catalytic site by PI 3-dependent kinase 1 (5).
Atypical PKCs signal in parallel to Akt in muscle and
adipose tissue during the stimulation of glucose metabo-
lism, especially via translocation of GLUT4 (6). There
appears to be redundancy between aPKC and aPKC	 in
this respect because one can substitute for the other in
overexpression studies. Diminished IRS-1/PI 3-kinase–de-
pendent aPKC activation is observed in muscle and adi-
pose tissue during insulin resistance and type 2 diabetes
(6) but remains intact in liver. In this instance, activation
occurs predominantly through the IRS-2/PI 3-kinase path-
way and is more important for the lipogenic action of
insulin, so its continued function may play a role in lipid
dysregulation upon hyperinsulinemia in insulin-resistant
states (6).
Insulin has also been reported to stimulate the activity
of cPKC and nPKC isoforms to promote glucose disposal
(7). Putative mechanisms of activation include tyrosine
phosphorylation of PKC and alternative splicing of PKC
to increase PKCII levels, but these have not been widely
substantiated, and the positive effects of these kinases
need to be reconciled with the negative regulation of
insulin action detailed below.
PKC AND INSULIN RESISTANCE
An association between PKC activation and insulin resis-
tance in skeletal muscle became apparent from studies
linking PKC translocation with defective insulin-stimu-
lated glucose metabolism (8–10). Most often, nPKC iso-
forms, especially PKC and PKCε , were implicated
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DAG. Thus, skeletal muscle from rats fed a high-fat diet for
3 weeks exhibited an increase in the translocation of PKC
and PKCε in conjunction with elevated lipid content and
diminished glucose disposal (11). PKC redistribution was
reversed upon treatment with the insulin sensitizer rosigli-
tazone (12). Similar alterations in nPKC isoforms were
also observed in genetic models of obesity and diabetes
(13,14). In more acute models of insulin resistance, PKC
translocation was also observed after 5-h lipid infusion
(15), whereas 1- or 4-day infusion of glucose, which
increased muscle lipid content, promoted activation of
PKCε (16).
PKCε has been the isoform most often implicated in the
generation of insulin resistance in liver. This was initially
demonstrated using liver biopsies from obese subjects
with type 2 diabetes (17). In addition, short-term (3-day)
fat feeding of rats, which induces hepatic steatosis, led to
translocation of PKCε in concert with a diminished ability
of insulin to reduce endogenous glucose production (18).
Other isoforms have been implicated to a lesser extent.
Alterations in the cellular localization of PKC and PKC,
in addition to PKCε , were observed in diabetic liver (17).
PKC translocation has also been observed in muscle of
high-fat fed rats (11), as well as after lipid infusion in
both liver (19) and muscle where PKC was also
activated (20). These studies support the hypothesis
that activation of one or more PKC isoforms through
increased lipid availability, especially PKC and PKCε ,
can interfere with insulin-stimulated glucose disposal. It
is not clear why nPKC isoforms are more often implicated
in these studies when cPKCs are also sensitive to eleva-
tions in DAG. This may be related to the additional
sensitivity of cPKCs to Ca
2, which may not become
elevated upon fat oversupply.
MECHANISMS OF PKC-INDUCED INSULIN RESISTANCE
PKC has been reported to inhibit several components of
the insulin signaling cascade, as well as downstream
metabolic enzymes such as glycogen synthase (rev. in 10).
These studies were often based on in vitro phosphoryla-
tion or overexpression of PKC and potential substrates in
cultured cells and require careful interpretation. In vivo,
PKC has also been suggested to act indirectly, such as by
upregulation of inﬂammatory pathways (21). Nevertheless,
most studies have addressed the simpler hypothesis that
PKC directly phosphorylates serine residues of the insulin
receptor substrates, especially IRS-1 (Fig. 2). This results
in diminished tyrosine phosphorylation of IRS-1, reduced
downstream signaling through the PI 3-kinase/Akt path-
way to glucose metabolism, and, ultimately, enhanced
IRS-1 degradation (22,23). Several PKC isoforms, espe-
cially PKC, have been shown to phosphorylate IRS-1
directly, at least in vitro or in intact cells (Table 1). In
addition, PKC may act upstream of other ser/thr kinases
(24–26). Thus, PKC activation may enhance the ability of
kinases, such as Jun NH2-terminal kinase (JNK) and
inhibitor of B kinase (IKK)-, to phosphorylate IRS-1 at
Ser-307, a key regulatory site located close to the domain
that interacts with the insulin receptor (27). PKC may also
act upstream of p42/44 MAPK to promote Ser-612 phos-
phorylation, which more speciﬁcally modulates PI 3-ki-
nase activation (28,29).
The insulin receptor itself, as well as IRS-1, may be a site
of negative regulation by PKC (Fig. 2), particularly PKCε .
While direct phosphorylation by PKC does not appear to
modulate tyrosine kinase activity (41), an interaction of
PKCε with the receptor in liver may affect its ability to
phosphorylate its substrates (42). Alternatively, such an
association may affect insulin receptor trafﬁcking in hepa-
tocytes (43) and hence both the clearance of insulin by the
liver (44) and degradation of the receptor itself (14).
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FIG. 1. The PKC family of lipid-activated protein kinases. PKC isoforms contain constant regions (C1–4) and variable regions (V1–5) and can be
divided into three subgroups. cPKCs are activated in the presence of calcium, which binds to the C2 domain, and DAG, which binds to the C1
domains. nPKCs lack C2 domains and are Ca
2-independent but still require DAG for full activation. aPKCs possess only one nonfunctional C1
domain (C1*) and no C2 domain and are both Ca
2- and DAG-independent. The C3 regions (ATP-binding) and C4 regions (protein substrate
binding) are highly conserved between isoforms. In each case, the pseudosubstrate (PS) sequences, found in the V1 variable region, interfere with
the catalytic domains to inhibit substrate phosphorylation until conformational changes induced by activators allow full activation.
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PKC ACTIVATION, AND INSULIN RESISTANCE
The studies described above have helped to establish the
hypothesis that aberrant PKC activation plays a role in the
development of insulin resistance. It is generally assumed
that elevations in DAG, secondary to intracellular lipid
accumulation, provide the essential link in this scheme.
But intracellular DAG could also be increased by insulin
(45) or from de novo synthesis from glucose (46). Thus,
PKCs may contribute to the secondary insulin resistance
caused by the hyperinsulinemia and/or hyperglycemia
occurring in the glucose-intolerant state. A further corol-
lary of these and similar studies is that different species of
fatty acids induce insulin resistance via different mecha-
nisms (rev. in 8). PKC activation is relatively speciﬁc to
DAG species composed of unsaturated fatty acid side chains
(47). Thus, we have demonstrated that the elevation in DAG
observed in muscle cells treated with the saturated fatty acid
palmitate does not greatly stimulate PKC translocation, while
the relatively minor DAG changes caused by unsaturated
fatty acids can do so (48,49). Because both saturated and
unsaturated fatty acids cause insulin resistance, this sup-
ports the contention that saturated fatty acids do not act
principally via the DAG/PKC pathway, but through other
mechanisms including ceramide-dependent signaling (50–
53). (Ceramide is a potential activator of aPKC [Fig. 2],
and a cross-talk mechanism involving sequestration of Akt
by PKC in caveolae has also been proposed to contribute
to the disruption of insulin signaling caused by saturated
fatty acids [52].)
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FIG. 2. Lipid oversupply leads to the generation of distinct intracellular mediators of insulin resistance. Fatty acids entering the cell are activated
by the formation of LCAC. Saturated fatty acid favors ceramide accumulation due to the requirement for palmitate during de novo synthesis,
which in turn leads to the inhibition of Akt, in part due to aPKC action. In contrast, DAG species derived from unsaturated fatty acids favor nPKC
activation and inhibition at the level of the insulin receptor (IR), or IRS-1. In addition, another unsaturated fatty acid–derived species,
dilinoleoyl-phosphatidic acid (PA), can reduce IRS-1 tyrosine phosphorylation in a PKC-independent manner (49). G3P, glycerol 3-phosphate;
LPA, lysophosphatidic acid; TG, triglyceride. See text for further details.
TABLE 1
PKC-mediated IRS-1 phosphorylation
Action Effect Reference
PKC IRS-1 Ser/Thr phosphorylation Inhibition of IR kinase activity 30
IRS-1 Ser24 phosphorylation Reduced IRS-1 phosphatidylinositol-4,5-bisphosphate binding 31
PKC IRS-1 Ser/Thr phosphorylation Inhibition of IR kinase activity 30
IRS-1 Ser307,323,574 phosphorylation Reduced IRS-1 Tyr phosphorylation 32
IRS-1 Ser24 phosphorylation Reduced IRS-1 phosphatidylinositol-4,5-bisphosphate binding 33
IRS-1 Ser318 phosphorylation Early positive but longer-term negative regulation of IRS-1 signaling 34
IRS-1 Ser357 phosphorylation Reduced IRS-1 Tyr phosphorylation 35
PKC IRS-1 Ser/Thr phosphorylation Inhibition of IR kinase activity 30
IRS-1 Ser1101 phosphorylation Reduced IRS-1 Tyr phosphorylation 36
PKC IRS-1 Ser/Thr phosphorylation Reduced IRS-1 Tyr phosphorylation 37,38
IRS-1 Ser318 phosphorylation Reduced IRS-1 Tyr phosphorylation 39,40
IRS-1 phosphorylation sites are listed as they appear in individual references. Ser302, 307, and 318 in mouse IRS-1 are Ser307, 312, and 323
in human IRS-1. IR, insulin receptor.
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PKC activation has been conﬁrmed in studies addressing
the effects of DAG kinase (DGK) isoforms, which lower
intracellular DAG levels and reverse the activation of PKC,
but these have also highlighted the complexity of DAG
signaling (49,54,55). On the one hand, a reduction in DGK
activity potentially contributes to hyperglycemia-induced
activation of PKC and the resultant inhibition of insulin
signaling in skeletal muscle from subjects with type 2
diabetes (55). On the other hand, overexpression of DGKε
in muscle cells, while reducing the activation of several
PKCs as expected because of chronic exposure to unsat-
urated fatty acid, in fact compounds defects in insulin
signaling (49). Such discrepancies are perhaps explained
by the different substrate speciﬁcities, regulation, and
cellular localization of the DGK isoforms (56) involved. In
addition, and taken together with the failure of dominant-
negative nPKC mutants to overcome insulin resistance in
cultured myotubes (48), it can be argued that the dimin-
ished insulin action arising from lipid oversupply is not
always simply explained by the accompanying DAG accu-
mulation and PKC activation. Indeed, other lipid interme-
diates such as dilinoleoyl-phosphatidic acid (49) have been
recently implicated as mediating insulin resistance in-
duced by unsaturated fatty acids via pathways indepen-
dent of PKC. This makes it essential to deﬁne precisely the
situations where PKC does play a role and to quantify its
contribution using in vivo models.
RECENT FINDINGS FROM PKC TRANSGENIC AND
KNOCKOUT MICE
The importance of the correlation between the transloca-
tion of various PKC isoforms and insulin resistance has
now been addressed in a more causative fashion, mostly
using PKC knockout mice. Deletion studies of conven-
tional PKC isoforms have argued against these enzymes
acting to signiﬁcantly reduce insulin action in vivo (57,58),
although it now appears that PKC can impinge on this
indirectly by reducing lipid oxidation in adipose tissue and
thereby enhancing fat accumulation (59).
PKC has been extensively investigated, because it is
relatively highly expressed in skeletal muscle compared
with other tissues, suggesting it as a prime candidate for
regulating glucose homeostasis. A complex picture has
emerged. First, PKC knockout mice are protected against
the short-term insulin resistance and defective insulin
signaling in skeletal muscle generated by acute lipid
infusion (60). In contrast, longer-term studies revealed
that these animals exhibit an increased susceptibility to
obesity and diet-induced insulin resistance (61). Likewise,
a dominant-negative approach to block PKC by overex-
pressing a kinase-inactive mutant in skeletal muscle also
resulted in obesity, glucose intolerance, and hyperinsulin-
emia (62). It therefore appears that while PKC can
acutely inhibit insulin signal transduction, it plays other
important roles that protect against obesity. Pertinently,
activation of PKC has usually been inferred from an
increased membrane-to-cytosolic ratio, but this is often
the consequence of the reduction in cytosolic protein
rather than an increase in membrane association
(11,12,63). These features could equally be interpreted as
an overall downregulation of PKC and diminished func-
tional capacity, consistent with it playing a positive role in
insulin sensitivity in the longer term.
Other studies addressing causation have indicated mul-
tiple roles for hepatic PKCε in the modulation of glucose
homeostasis. Antisense oligonucleotides against PKCε
were able to reverse a defect in insulin receptor kinase
activity and the suppression of hepatic glucose production
observed in rats fed for 3 days on a high-fat diet based on
safﬂower oil (rich in the unsaturated fatty acid linoleate)
(42). This extends the correlation between PKCε translo-
cation and liver insulin resistance observed under short-
term conditions (18). In contrast, no improvement in
hepatic insulin signaling was observed in mice globally
deleted in PKCε and maintained on a long-term diet rich in
saturated fatty acids and sucrose, which induces obesity
and profound insulin resistance (44). Surprisingly, how-
ever, glucose tolerance was completely restored in the
PKCε knockout mice. This was explained by a greater
availability of insulin, which compensated for, rather than
reversed, insulin resistance. Two phenotypes in the PKCε
null mice contributed to this compensation: an enhance-
ment in glucose-stimulated insulin secretion by pancreatic
-cells (see below) and a reduction in hepatic insulin
clearance (44). Importantly, there was no increase in
hepatic triglyceride or fatty acid content in PKCε knockout
mice, indicating that the transiently enhanced insulin
levels in response to a glucose challenge did not promote
steatosis.
The contrasting interpretations of the role of PKCε in
hepatic insulin action arising from these studies might be
explained by differences in both the type and the duration
of the fat diets used (42,44). First, the use of a diet rich in
unsaturated fat is more likely to activate PKC (48), while a
saturated fat diet may act predominantly through the
elevation of ceramide (50,51,53). Second, it is possible that
PKCε contributes signiﬁcantly to hepatic insulin resistance
in an acute fashion but that other PKCε -independent
mechanisms become prevalent over time, such that PKCε
deletion is no longer sufﬁcient to protect insulin signaling.
Finally, compensation for PKCε deletion by other PKC
isoforms, such as PKC, might occur in liver and muscle,
but not in -cells. Under these conditions, enhanced
insulin secretion (see below) might overcome the ongoing
loss of insulin sensitivity because of the high-fat diet.
Overall, it can be concluded that individual PKC iso-
forms, especially PKC and PKCε , play multiple roles in
the modulation of insulin action, even within one particu-
lar tissue such as muscle or liver. In the case of PKC,
these roles appear to be discordant, making this enzyme
less suitable as a therapeutic target. In contrast, although
deletion or reduction of PKCε has been shown to produce
divergent effects, collectively these should all be beneﬁcial
for glucose homeostasis. It still remains to be determined,
however, whether the key mechanism of action of PKCε
relates to the generation of insulin resistance, as originally
envisioned, or whether the newly recognized role in regu-
lating insulin availability predominates.
PKC IN -CELLS
Surprisingly, given the longstanding focus on PKCs in
insulin resistance, there have been relatively few studies
addressing a corresponding role in -cell dysfunction.
Before describing this work, however, it is necessary to
outline what is known about the normal physiological
functions of PKC in -cells, particularly its controversial
role in nutrient-stimulated insulin secretion and its regu-
lation of -cell mass. Other aspects less directly relevant to
type 2 diabetes, such as the well-established involvement
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have been reviewed elsewhere and will not be addressed
further here (64,65).
PKC ISOFORMS AND GLUCOSE-STIMULATED INSULIN
SECRETION
It has been known for more than 25 years that activation
of PKC, using pharmacological stimulators such as
phorbol esters, was sufﬁcient to augment insulin secre-
tion, particularly in conjunction with a stimulus that
raised intracellular Ca
2 (66). Because glucose pro-
moted phosphoinositide hydrolysis in -cells, secondary
to voltage-gated Ca
2 inﬂux and a Ca
2-dependent
stimulation of phospholipase C (67), it was envisioned
that the DAG/PKC pathway might contribute to glucose-
stimulated insulin secretion (GSIS). However, DAG could
also be generated via de novo synthesis, either from glucose
directly (68,69) or secondarily to a switch in endogenous
fatty acid metabolism away from -oxidation and toward
esteriﬁcation products. The latter phenomenon has been
widely documented and arises via glucose-enhanced anaple-
rosis leading to increases in malonyl CoA, which subse-
quently inhibits CPT1, a key control point of -oxidation
(70). The further realization that CoA derivatives of long-
chain fatty acids (long-chain acyl-CoA [LCAC]) could
themselves activate PKCs has underpinned ongoing sup-
port for this proposed signaling function of lipid partition-
ing. Thus, irrespective of whether PKC activation was
triggered by DAG generated from phosphoinositide hydro-
lysis or by LCACs from endogenous metabolism, the net
result would be an ampliﬁcation of the more proximal
Ca
2-dependent signals that initiate GSIS (70,71).
Nevertheless, for technical reasons, it has been difﬁcult
to prove or disprove this role of PKC. Rat and mouse islets
and (to variable extents) -cell lines express multiple PKC
isoforms, including PKC,- II,- ,- ε ,- , and -	 (72–75).
Moreover, the framework within which PKCs function
might differ between rat and mouse -cells. Rat islets
display a second phase of GSIS, which is both greatly
exaggerated compared with mouse and much more sensi-
tive to the (nonspeciﬁc) PKC inhibitor staurosporine (76).
Human islets behave more similarly to mouse than to rat
islets, displaying a modest second phase that is resistant to
staurosporine (69,77). Another technical limitation is that
although measuring PKC translocation by immunoblotting
is more speciﬁc than activity assays, this may suffer from
redistribution artifacts during sample processing. Subcel-
lular localization by microscopy is potentially com-
pounded by cross-reactivity of antisera (for studies of
endogenous protein) or overexpression artifacts (when
using transfected reporters). Optimal visualization of the
latter often also relies on complex correction of back-
ground signals and/or somewhat artiﬁcial conditions.
Nevertheless, there is a general consensus that glucose
promotes a rapid Ca
2-dependent translocation of cPKC
isoforms (particularly PKC) to the plasma membrane
(78–80). Glucose also stimulates a redistribution of PKCε ,
in this case independently of Ca
2 (79,81), to sites con-
taining insulin granules at either the plasma membrane
(82) or near the nucleus (83). Translocation does not
necessarily equate to functional activation, however, and
demonstrations of glucose-stimulated phosphorylation of
PKC substrates in -cells have been inconsistent or poorly
correlated with secretion (75,84–86). We demonstrated
that glucose normally induces only a modest and transient
increase in phosphorylation of cPKC substrates in islets,
but this is signiﬁcantly enhanced in the presence of
phosphatase inhibitors (75). This implies that a concomi-
tant stimulation of protein phosphatases by glucose (64)
might counteract the consequences of PKC activation.
Determining whether PKC activation is necessary for
GSIS has also been problematic. Global downregulation of
PKC activity by chronic exposure to phorbol esters, or
using nonspeciﬁc inhibitors, has produced variable results
(84–88) possibly explained by species differences. Never-
theless, there is consistent evidence that inhibitors of
conventional PKCs completely block insulin secretion in
response to phorbol esters, but affect GSIS only modestly
at best (75,86,89,90). Overexpression of a kinase-dead
PKC construct in rat islets augmented ﬁrst-phase, and
slightly diminished second-phase, GSIS in batch incuba-
tions (91), but this was not observed when assessed
directly using islet perifusion (75). Thus, the general
conclusion from these studies is that conventional PKCs
are not required for a robust ﬁrst- or second-phase GSIS,
although their activation by glucose might exert a minor
modulatory inﬂuence.
A role for PKCε in GSIS has also been proposed (79,82).
In one study, in which rat islets were “skinned” to facilitate
entry of a PKCε inhibitory peptide, a partial requirement
for PKCε in GSIS was demonstrated (79). Using the same
peptide, but in a cell-permeant form, we observed no
requirement for PKCε in GSIS from mouse islets (44).
Another report concluded that overexpression of PKCε in
-cells of ob/ob mice was sufﬁcient to enhance secretion,
although this was not assayed directly, but extrapolated
from changes in membrane capacitance during the initial
recording (82). Capacitance changes due to glibenclamide
(82) or inositol hexakisphosphate (92) were also blocked
by kinase-dead and/or antisense constructs, but this ap-
proach was not extended to examine a direct requirement
of PKCε in GSIS. In contrast, using PKCε knockout mice,
glucose tolerance and insulin excursions during whole-
body glucose tolerance tests were similar to wild-type
animals (44). Likewise, no differences in GSIS were ob-
served when control and PKCε null islets were compared
in batch incubations or perifusion studies ex vivo (44).
PKC AND INSULIN SECRETION DUE TO FATTY ACIDS
There are also indications of PKC involvement in the
potentiation of GSIS by fatty acids (71). First, treatment of
-cells with fatty acids has been variously shown to
activate PKC (93–96). Second, general PKC inhibitors
partially attenuate the enhancement of insulin secretion
due to fatty acids (97–99), even in mouse islets where
these inhibitors barely affect GSIS (97,98). Isoform speci-
ﬁcity is uncertain, since selective inhibitors or overexpres-
sion strategies have not been used in this context. Most
evidence, however, points to an involvement of non-cPKCs
and therefore novel or atypical isoforms (99–101). Early
studies emphasized the importance of endogenous lipid
metabolism, and especially a switch from -oxidation to
esteriﬁcation products, in the mechanism of activation
(94). This is consistent with demonstrations that the novel
PKCs in particular can be directly activated by LCACs
(96). Another possibility, yet to be explored fully, is that
PKC could be activated downstream of the cell surface
GPR40 receptor, which binds a variety of fatty acids and is
known to couple to phospholipase C and hence presum-
ably to phosphoinositide hydrolysis (102).
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There is strong evidence to suggest that PKC positively
regulates -cell proliferation in response to a variety of
growth factors, although the signaling partners up- and
downstream of PKC are yet to be determined (103–105).
Speciﬁcity was conﬁrmed in one study by demonstrating
that proliferation was not altered by knockdown of PKC	
expression (105), consistent with observations that islets
from PKC	 knockout mice are no smaller than those from
wild-type animals (106). There is also evidence that PKC
can positively regulate expression of the key -cell tran-
scription factor Pdx-1 in response to either IGF-1 (104) or
glucose (107). This would seem more relevant to the
control of differentiation, as opposed to proliferation, and
is consistent with a requirement for PKC in the glucose-
dependent expression of K
 channel subunits required for
GSIS (108). A developmental role for PKC	 has also been
strongly supported. PKC	 knockout mice display defective
GSIS in vivo and ex vivo, but this is explained less by a
speciﬁc role in stimulus secretion coupling than by a
general effect on -cell differentiation exerted upstream of
the HNF3 transcription factor (106). This is not dissimilar
to the purported roles of PKC in the glucose-dependent
differentiation program described above (107,108) and so
may point to redundant roles for aPKCs in this particular
instance.
There is less extensive evidence for involvement of
nPKC isoforms in regulating -cell mass. Fatty acids
disrupt signaling downstream of receptors important for
-cell proliferation, and nPKC isoforms have been impli-
cated in this context (96). Islet mass was not altered by
PKCε deletion in mice maintained on a chow diet (44). On
a high-fat diet, however, islet cell mass and proliferation
were augmented in wild-type animals in partial compen-
sation for the accompanying insulin resistance. These
increases in mass and proliferation were not observed in
the PKCε knockout mice (44). This may represent an
adaptive response, in that compensation would no longer
be required because of the improved glucose tolerance
observed under these conditions. Alternatively, PKCε
might play a more active role in -cell proliferation, which
is absent in the knockout mice. Further work is required to
resolve these issues.
As in many cell types, PKC exerts a pro-apoptotic role
in pancreatic -cells (95,109,110). This was ﬁrst shown in
cytokine-mediated cell destruction and involved an in-
crease in mRNA stabilization for transcripts of inducible
NO synthase (109). A more distal role, secondary to
generation of a constitutively active PKC fragment after
its cleavage by caspase 3, was also implicated (110).
Inhibition of PKC also partially protected against lipo-
apoptosis (95). In this instance, activation appeared to be
downstream of Gq, which potentially implicates a receptor
such as GPR40. Further investigation of this role of PKC
would be of interest. Seemingly at odds with this pro-
apoptotic function, other authors have demonstrated a
partial requirement in GSIS using islets from PKC knock-
out mice (111). This contrasted with an earlier study using
overexpression of kinase-dead PKC in isolated rat islets
using adenovirus (75). Moreover, translocation of PKC
has never been observed when tested in response to
glucose (80,83,100,111).
PKC IN SECRETORY DYSFUNCTION OF -CELLS
We have recently established an unexpected role for PKCε
in the development of -cell lipotoxicity (44). As discussed
above, deletion of PKCε resulted in a normalization of
glucose tolerance in fat-fed mice because of an enhance-
ment of insulin availability rather than improved insulin
sensitivity. This was conﬁrmed by comparing GSIS from
wild-type or PKCε null islets chronically exposed to ele-
vated fatty acids ex vivo. The secretory defects induced
under these conditions were prevented by deletion of
PKCε , and likewise GSIS was improved in islets of diabetic
db/db mice when treated ex vivo with a PKCε inhibitory
peptide. In all cases, in vivo and ex vivo, the enhancement
of insulin secretion was dependent on a diabetic milieu or
prior lipid exposure; unimpaired GSIS was not altered by
functional inhibition of PKCε (44). This suggests that
activation of PKCε is either intimately involved in the
actual process whereby secretory defects are induced by
chronically elevated fatty acid or lipid overload or that it
acts proximally to that process.
PKCε most probably affects secretion via multiple mech-
anisms. Deletion of this isoform resulted in slight (25%)
increases in both insulin content and insulin mRNA,
suggesting that it might play a minor role in regulating
insulin gene expression (44). But the modesty of these
increases, and their lack of dependence on prior lipid
exposure, suggests they do not make a major contribution
to the reversal of defective secretion. Instead, our ﬁndings
implicated the ampliﬁcation pathway of GSIS, based on
observations of lipid partitioning in -cells during acute
exposure to glucose (44). Normally this is associated with
a switch from -oxidation toward esteriﬁcation pathways,
but chronic pretreatment with fatty acids disrupts this
switch by upregulating -oxidation (70). Deletion of PKCε
helps to restore the appropriate balance between esteriﬁ-
cation and oxidation, and this may contribute to the
normalization of insulin secretion (Fig. 3). At present,
however, the role of lipid partitioning in regulating GSIS
remains somewhat controversial. It is unclear whether this
phenomenon is itself causal, activating signaling cascades
that augment secretion, or whether it is merely a readout
of potentially more important events occurring upstream
in anaplerotic pathways (Fig. 3). It is possible that further
deﬁning the role of PKCε might actually help resolve some
of these basic unsolved questions in stimulus-secretion
coupling in -cells.
PKC AS A THERAPEUTIC TARGET FOR TYPE 2
DIABETES
Much of the work described above is based on the premise
that inhibition of PKCs could be of beneﬁt in the treatment
of type 2 diabetes. Within that framework, we will now
attempt to summarize our view of the current state of the
ﬁeld (Fig. 4). Most speculation over the last decade has
centered on PKC antagonists as potential insulin sensitiz-
ers. This is based on a body of work demonstrating that
PKCs possess the capacity to disrupt insulin signaling and
that they are activated in muscle and liver during insulin
resistance. A causal relationship, however, between PKC
activation and insulin resistance has been difﬁcult to
substantiate. In particular, the early promise of PKC as
potential mediator of muscle insulin resistance has been
clouded by an additional role in protecting against obesity
(61,62). In liver, inhibition of PKCε might improve insulin
sensitivity in short-term models (42); this was not the case
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representative of obesity-induced insulin resistance (44).
Further work is required to resolve these issues, particu-
larly because a compensatory activation of other PKC
isoforms may have masked the effects of PKCε deletion on
insulin sensitivity in the knockout model. A possible
candidate in that regard is PKC, which has been impli-
cated in studies of IRS phosphorylation (30,32–35), al-
though its role in vivo has not been assessed directly.
Regardless of the ultimate involvement or not of PKCs
in insulin resistance, the rationale for targeting PKCs in
the treatment of type 2 diabetes has been extended by our
recent demonstration of an unexpected role for PKCε in
regulating insulin availability (Fig. 4). Indeed, targeting
PKCε is likely to have several advantages over existing
therapies that enhance insulin secretion. Most impor-
tantly, PKCε inhibition appears to act very close to the
actual cause of impaired secretion, or at least speciﬁcally
addresses its consequences. To our knowledge, no other
strategy for promoting insulin secretion shows this bene-
ﬁt. Existing therapies, such as sulfonylureas or GLP-1
agonists, bypass the secretory defect rather than address-
ing it directly. Another advantage is that PKCε deletion
selectively augmented the ﬁrst phase of GSIS, which is
crucial for regulating glucose tolerance and which is lost
early in the development of type 2 diabetes. Finally, the
effects of inhibiting PKCε in -cells were complemented by
a reduction in hepatic insulin clearance (44). Both aspects
contributed to the enhanced availability of insulin. Taken
together, these features suggest that a single therapy,
based on inhibition of PKCε , could act at multiple sites and
in manners different from, and therefore complimentary
to, existing treatments for type 2 diabetes.
Obviously, it is difﬁcult to develop truly selective inhib-
itors of protein kinases and, indeed, it remains to be seen
whether other potential consequences of PKCε inhibition
might preclude its adoption as a therapy. On the other
hand, off-target effects might actually prove to be beneﬁ-
cial if they included, for example, inhibition of PKC,
which might help preserve -cell mass and/or overcome
insulin resistance (Fig. 4). Regardless of the ultimate
clinical utility of PKC inhibitors, however, it seems that
there is much useful information to be obtained in the
short term by the further study of the roles of PKC in
regulating glucose homeostasis. This is a particular need
for mechanistic insight into how PKCε controls insulin
uptake in hepatocytes and restores GSIS in diabetic
-cells.
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FIG. 3. Putative site of action of PKC in the ampliﬁcation pathway of GSIS. Pyruvate, derived from glycolysis, undergoes two metabolic fates
in mitochondria that together regulate GSIS. In the initiation pathway, it is subjected to oxidative phosphorylation to generate ATP, which leads
to closure of ATP-dependent K
 channels, depolarization, and the gating of Ca
2 inﬂux. In the ampliﬁcation pathway, pyruvate augments Krebs
cycle intermediates (anaplerosis), some of which can be exported to the cytosol to generate malonyl-CoA. This results in an inhibition of the
-oxidation of LCACs derived from exogenous fatty acids or mobilization of endogenous lipid stores. This favors the formation of esteriﬁcation
products di- or triacylglycerol (DAG or TG, respectively). PKC, potentially activated by LCACs or DAG, appears to promote oxidation of lipid
fuels at the expense of esteriﬁcation pathways that are implicated in the ampliﬁcation pathway. Whether PKC acts directly at this site, or
upstream at a step in anaplerosis, remains to be determined. For further explanation, see the text and Ref. 44.
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